Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO GI 2023 | Baseline analysis of patients enrolled in the BERING CRC study

BRAF V600E-mutant metastatic colorectal cancer (mCRC) is characterized by a poor prognosis and limited clinical data. Sebastian Stintzing, MD, Charite University Hospital, Berlin, Germany, discusses the results of a baseline analysis of patients enrolled in the BERING CRC study (NCT04673955), a European real-world study in patients with BRAF V600E-mutant mCRC. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

View our new feature exploring genomic biomarkers in metastatic colorectal cancer here: https://bit.ly/3DcSevZ